Skip to content
Open access

Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess

Nov 2026 · Frontiers in Oncology · 0 citations · 40 references

Abstract

Ocular adverse events may affect tolerability during long-term endocrine therapy for breast cancer, but comparative real-world evidence remains limited. We characterized ocular adverse-event reporting patterns using the FDA Adverse Event Reporting System (FAERS) and VigiAccess. FAERS reports from Q1–2004 to Q1–2026 involving seven endocrine therapies were analyzed. Drug-specific signals were assessed using reporting odds ratio (ROR) and information component (IC) within a breast cancer indication-restricted, primary-suspect reference population. Class comparisons used multivariable logistic regression with Benjamini–Hochberg false-discovery-rate correction. Age, ovarian function suppression (OFS), and time to onset (TTO) were evaluated; VigiAccess was descriptive. Among 42,851 eligible reports, 2,528 contained ocular adverse events. Tamoxifen showed the broadest signal spectrum, while aromatase inhibitors (AIs) showed ocular-surface and posterior-segment signals. No ocular Preferred Terms met signal criteria for toremifene or elacestrant. FDR-adjusted comparisons showed broader retinal, macular, optic nerve, corneal, and vitreous reporting with selective estrogen receptor modulators (SERMs), particularly versus AIs. Among SERM users, age ≤45 years showed lower reporting odds than age 45–60 years (aOR 0.67, 95% CI 0.46–0.94). Concomitant OFS showed lower reporting odds among AI users (aOR 0.43, 95% CI 0.28–0.63), interpreted as exploratory. Median TTO was 79, 77, and 491 days for AIs, selective estrogen receptor degraders (SERDs), and SERMs. Ocular adverse-event reporting differed across endocrine therapies. These findings generate hypotheses for future pharmacoepidemiological, clinical, and mechanistic investigation but should not be interpreted as incidence, causality, or differential clinical risk.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.